Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Ebola Analysis Finds Virus Hasn’t Become Deadlier, Yet

By R&D Editors | April 14, 2015

The Ebola GP protein from the point of view of a human cell about to be infected. Courtesy of The University of ManchesterResearch from The University of Manchester using cutting edge computer analysis reveals that despite mutating, Ebola hasn’t evolved to become deadlier since the first outbreak 40 years ago.

The surprising results demonstrate that whilst a high number of genetic changes have been recorded in the virus, it hasn’t changed at a functional level to become more or less virulent.

The findings, published in the journal Virology, demonstrate that the much higher death toll during the current outbreak, with the figure at nearly 10,500, isn’t due to mutations/evolution making the virus more deadly or more virulent.

Prof. Simon Lovell from the Faculty of Life Sciences explains: “Using data from every outbreak since 1976 we were able to highlight what changes there had been in the RNA of the virus and then using specially developed tools predict the consequences of those changes. What we found was that whilst Ebola is mutating, it isn’t evolving to the point of adapting to become more or less virulent. The function of the virus has remained the same over the past four decades which really surprised us. Unfortunately this does mean the Ebola virus that has now emerged on several occasions since the 1970s will very probably do so again,” explains Prof. Simon Lovell from the Faculty of Life Sciences.

Prof. David Robertson says the findings can be seen as good news: “The fact that Ebola isn’t changing in a way that effects the virulence of the disease means that vaccines and treatments developed during this current outbreak have a very high chance of being effective against future outbreaks. It also means that methods to successfully tackle the virus should work again, so hopefully in the future an outbreak can be stopped from spreading at a much earlier stage.”

The team used a computational approach that PhD student, Abayomi Olabode, developed for analysing changes in HIV-1. This had highlighted adaptions within the virus in the context of protein structure. When they used it to study Ebola they expected to see similar things but didn’t.  

Robertson points out the advantages of the computer-based approach: “We were able to do this research quickly and whilst the Ebola outbreak was still ongoing. The data generated by Gire et al. in 2014 was all freely available and our analysis technique is a safe way to study the virus without unnecessary exposure. This type of study could be used on future outbreaks to analyse what is happening in real time within the virus. This level of surveillance will only become more essential in the fight against contagious illness as we live in an increasingly globally connected society.”

The team also stress that, counter-intuitively, analysis is needed to identify when a virus becomes less potent. This is because infected individuals could potentially infect more people if they did not progress to severe illness. The deadly nature of Ebola means the symptoms can be identified at a relatively early stage and those who had been in contact with the patient during the infectious stage readily identified by contact tracing. If it becomes less deadly then it may take longer to spot those symptoms, if they can be spotted at all, or for the person to become ill increasing the chance of spreading the virus. An attenuated virus, although less deadly on an individual basis, could spread widely and thus ultimately cause many more deaths. 

Prof. Tony Redmond from the University’s Humanitarian and Conflict Response Institute helped to coordinate the NHS response to Ebola in West Africa: “Like any medical response, the response to ebola must be supported by science. These are very important findings and emphasise that the spread of the virus in this outbreak owed as much to factors within the human community than within the virus itself.”

“Our study demonstrates the vital role computational analysis can play during a virus outbreak. As scientists our role is to worry about the potential changes our research tool allows us to map what is happening within a virus and the consequences of any changes. Ebola will occur again, and it’s only through such close monitoring that we will contain it and ultimately eradicate it,” Lovell concludes.

Related Articles Read More >

Could AI smell cancer? Science says yes
R&D World announces 2025 R&D 100 Professional Award Winners
Elsevier’s 121 million data point database is now searchable by AI
6 R&D advances this week: a quantum computer in space and a record-breaking lightning bolt
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE